Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

CROSSJECT is strengthening its collaboration with ETON PHARMACEUTICALS to address the US adrenal insufficiency market. The company offers an innovative hydrocortisone formulation that simplifies treatment administration. CROSSJECT will receive a royalty of approximately 10% on sales made by ETON.

ETON is responsible for developing and marketing this solution, under the name ET-800, in the US market, estimated at over $200 million. Efforts are focused on an FDA submission planned for the second half of 2026.

Zeneo® Hydrocortisone, an alternative to current formulations such as Pfizer's Solu-Cortef®, promises to improve practices thanks to its simplified design. Next steps include development and production, with the stated goal of capturing a significant share of the market.